AG - von GBC AG
Einstufung von GBC AG zu MagForce
Anlass der Studie: Research Comment
Kursziel: 11.00 Euro
Kursziel auf Sicht von: 31/12/2021
Analyst: Cosmin Filker, Marcel Goldmann
Successful completion of Phase 2a trial for the treatment of prostate
cancer; market approval expected in 2021; forecasts and BUY price target
MagForce AG has announced the successful completion of Stage 2a of the
pivotal trial for the treatment of prostate cancer in the United States. As
expected, the treatment group of 10 patients experienced only minimal
treatment-related side effects, comparable to those of the first study
phase. Prior to the start of the second study phase, MagForce
established a streamlined one-day treatment procedure, which enables
patient treatment within just one day. Especially against the background of
the current Covid 19 pandemic, but also outside the current pandemic
situation, a single clinic visit is of great advantage. Even in this
streamlined procedure, the side effects observed were only minor.
In our previous projections, we had expected patient treatment to be
completed by the end of 2020 and the final pivotal study 2b to begin in
early 2021. We see the company's latest announcement as a confirmation of
this, especially as the company is currently preparing for the start of
study phase 2b, which should start early in the second quarter of 2021.
Following FDA approval, MagForce
management expects marketing to begin in
the second half of 2021, which is also fully in line with our previous
In the final study phase 2b, which is important for market approval, up to
120 male patients are to be enrolled at the three MagForce
Texas, Washington and Florida. The aim of the study is to show that
treatment with the MagForce
technology, prostate cancer patients can remain
in the so-called 'active surveillance programme' for longer. The disease
pattern of patients included in this programme requires close monitoring,
but surgery or radiation is not necessary. For patients, staying longer in
this stage is associated with a gain in quality of life and the avoidance
of side effects. For the health care system, the avoidance of surgical
interventions means savings effects that are significant in view of the
high number of prostate diseases. We therefore expect a high level of
acceptance for the MagForce
treatment after market approval.
In view of the confirmation of the approval timetable relevant for our
forecasts so far, we leave our previous sales and earnings forecasts
unchanged. While revenue from the treatment of prostate cancer patients in
the US should not visibly increase until the coming 2022 financial year,
MagForce AG should primarily report revenue from glioblastoma treatment in
Europe in the current 2021 financial year. The management statement that a
tripling of commercial glioblastoma treatments is expected in 2021 compared
to 2020 still applies. We continue to expect the EBITDA break-even to be
reached from 2022 onwards, i.e. from the significant increase in sales in
the prostate area.
Based on the unchanged forecasts, we confirm our price target of EUR11.00
per share. We continue to assign the BUY rating.
Die vollständige Analyse können Sie hier downloaden:
Kontakt für Rückfragen
0821 / 241133 0
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG und Art. 20 MAR. Beim oben analysierten Unternehmen ist folgender möglicher Interessenkonflikt gegeben: (5a,6a,11); Einen Katalog möglicher Interessenkonflikte finden Sie unter:
Date (time) of completion: 11/02/2021 (08:38 am)
Date (Time) first distribution: 11/02/2021 (9:30 am)
übermittelt durch die EQS Group AG.
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw.
Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung
oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.